Presentation is loading. Please wait.

Presentation is loading. Please wait.

P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint- Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC) 

Published byAgnes Jenkins Modified over 6 years ago

Similar presentations

Presentation on theme: "P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint- Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC) "— Presentation transcript:

1 P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint- Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC)  Am Martinez De Castro, Alejandro Navarro, Susana Cedres Perez, Alex Martinez, Nuria Pardo, Alberto Hernando, Carolina Ortiz, Fabiola Amair, M. Biosca, Juan Aguilar-Company, Eulalia Scheenaard, Sergi Recasens, Lluisa Carbonell, Andrea Retter, Sonia Martinez, Adelaida Piera, Sonia Valverde, Lidia Velez, Silvia García Matas, Marta Vilaro, Enriqueta Felip  Journal of Thoracic Oncology  Volume 12, Issue 1, Pages S1313-S1314 (January 2017) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2017 12, S1313-S1314DOI: (10.1016/j.jtho.2016.11.1858)
Copyright © Terms and Conditions

Download ppt "P3.02c-063 Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint- Inhibitors for Patient with Advanced Non–Small-Cell Lung Cancer (NSCLC) "

Similar presentations

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.

Elderly Patients with Advanced NSCLC in Phase III Clinical Trials: Are the Elderly Excluded from Practice-Changing Trials in Advanced NSCLC?  Adrian G.
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.

Role of Postoperative Radiotherapy in Pathologic Stage IIIA (N2) Non–Small Cell Lung Cancer in a Prospective Nationwide Oncology Outcomes Database  Alex.
APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
NA  Journal of Thoracic Oncology 

NA  Journal of Thoracic Oncology 
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.

P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.
A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.

A Brief Report of the Status of Central Nervous System Metastasis Enrollment Criteria for Advanced Non–Small Cell Lung Cancer Clinical Trials: A Review.
Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.

Clinical Outcome of ALK-Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors.
Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer  Alberto Chiappori,

Obatoclax Mesylate, a Pan–Bcl-2 Inhibitor, in Combination with Docetaxel in a Phase 1/2 Trial in Relapsed Non–Small-Cell Lung Cancer  Alberto Chiappori,
P2.03b-003 Mutation Profile & Histology According to ERS/ATC/IASCL Associated with IPFS to WBI in BM Patients with Recent Adenocarcinoma Lung Cancer 

P2.03b-003 Mutation Profile & Histology According to ERS/ATC/IASCL Associated with IPFS to WBI in BM Patients with Recent Adenocarcinoma Lung Cancer 
The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials  Krista.
P1.08-022 Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.

P Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables  Timothy Edwards, Charlene.
Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,

Meta-Analysis of First-Line Therapies in Advanced Non–Small-Cell Lung Cancer Harboring EGFR-Activating Mutations  Benjamin Haaland, PhD, Pui San Tan,
Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State  Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.

Variations in Receipt of Curative-Intent Surgery for Early-Stage Non–Small Cell Lung Cancer (NSCLC) by State  Helmneh M. Sineshaw, MD, MPH, Xiao-Cheng.
Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green 
P2.01-007 Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,

P Molecular Characterization of Non-Small Cell Lung Cancers (NSCLC) in Young Patients from an Argentine Population  V. Denninghoff, G. Recondo,

Similar presentations

Ads by Google